Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites

  • T. G. Hastings
  • M. J. Zigmond


Parkinson’s disease affects one out of every 100 people above the age of 55. Its cause is unknown and although the symptoms can be treated, there is no cure. The disease is associated with the selective loss of neurons that contain biogenic amines, and among these it is the dopamine (DA) neurons of the nigrostraital projection that are the most consistently and severely affected (Bernheimer et al., 1973). In this review we discuss the possibility that DA may act as an endogenous neurotoxin, causing the degeneration of the very neurons that release it. We further suggest that although treatments which increase the synthesis and release of DA reduce the symptoms, they also may serve to exacerbate the neurodegenerative process. We propose that the treatments which increase the antioxidant capacity of brain may be protective.


Dopaminergic Neuron Reactive Metabolite Striatal Slice Cysteinyl Residue Dopamine Efflux 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abercrombie ED, Bonatz AE, Zigmond MJ (1990) Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525: 36–44PubMedCrossRefGoogle Scholar
  2. Agid Y, Ruberg M, Javoy-Agid F, et al (1993) Are dopaminergic neurons selectively vulnerable to Parkinson’s disease? Adv Neurol 60: 148–163PubMedGoogle Scholar
  3. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington: clinical morphological and neurochemical correlations. J Neurol Sci 20: 415–455PubMedCrossRefGoogle Scholar
  4. Chapman AG, Durmuller N, Lees GJ, Meldrum BS (1989) Excitoxicity of NMDA and kain-ic acid is modulated by nigrostriatal dopaminergic fibres. Neurosci Lett 107:256–260PubMedCrossRefGoogle Scholar
  5. Cohen G (1983) The pathobiology of Parkinson’s disease: biochemical aspects of dopamine neuron senescence. J Neural Transm [Suppl] 19: 89–103Google Scholar
  6. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52: 381–389PubMedCrossRefGoogle Scholar
  7. Filloux F, Townsend JJ (1993) Pre- and post-synaptic neurotoxic effects of dopamin demonstrated by intrastriatal injection. Exp Neurol 119: 79–88PubMedCrossRefGoogle Scholar
  8. Fornstedt B, Carlsson A (1991) Vitamin C deficiency facilitates 5-S-cysteinyldopamine formation in guinea pig striatum. J Neurochem 56: 407–414PubMedCrossRefGoogle Scholar
  9. Fornstedt B, Rosengren E, Carlsson A (1986) Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine dopa and dopac in the brains of eight mammalian species. Neuropharmacol 25: 451–454CrossRefGoogle Scholar
  10. Fornstedt B, Pileblad E, Carlsson A (1990) In vivo autoxidation of dopamine in guinea pig striatum increases with age. J Neurochem 55: 655–659PubMedCrossRefGoogle Scholar
  11. Giovanni A, Liang LP, Hastings TG, Zigmond MJ (1995) The estimation of hydroxyl radical content in rat brain using salicylate: impact of methamphetamine. J Neurochem 64: 1819–1825PubMedCrossRefGoogle Scholar
  12. Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromela-nin and cytotoxic quinones. Mol Pharmacol 14: 633–643PubMedGoogle Scholar
  13. Graham DG, Tiffany SM, Bell WR jr, Gutknecht WF (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine 6-hydroxy-dopamine and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14: 644–653PubMedGoogle Scholar
  14. Grisham MB, Perez VJ, Everse J (1987) Neuromelanogenic and cytotoxic properties of canine brainstem peroxidase. J Neurochem 48: 876–882PubMedCrossRefGoogle Scholar
  15. Halliwell B, Gutteridge JMC (1985) Oxygen radicals and the nervous system. Trends Neurosci 8: 22–26CrossRefGoogle Scholar
  16. Hastings TG (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 64: 919–924PubMedCrossRefGoogle Scholar
  17. Hastings TG, Zigmond MJ (1994) Identification of catechol-protein conjugates in neostri-atal slices incubated with 3H-dopamine: impact of ascorbic acid and gluthathione. J Neurochem 63: 1126–1132PubMedCrossRefGoogle Scholar
  18. Hastings TG, Lewis DA, Zigmond MJ (1996) Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Sci USA 93: 1956–1961CrossRefGoogle Scholar
  19. Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 334: 345–348PubMedCrossRefGoogle Scholar
  20. Johnson M, Stone DM, Hanson GR, Gibb JW (1987) Role of dopaminergic nigrostriatal pathway in metamphetamine-induced depression of the neostriatal serotonergic system. Eur J Pharmacol 135: 231–234PubMedCrossRefGoogle Scholar
  21. Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Agid Y (1992) Is the vulnerability of neurons in substantia nigra of patients with Parkinson’s disease related to their neuromelanin content? J Neurochem 59: 1080–1089PubMedCrossRefGoogle Scholar
  22. Kish SJ, Morito C, Hornykiewicz O (1985) Glutathione peroxidase activity in Parkinson’s disease brain. Neurosci Lett 58: 343–346PubMedCrossRefGoogle Scholar
  23. Liang LP, Zigmond MJ (1993) Dopamine synthesis in neostriatal slices after intraventricular 6-hydroxydopamine. Soc Neurosci Abstr 19: 401Google Scholar
  24. Liang LP, Hastings TG, Zigmond MJ (1994) Hydroxyl radical formation is increased in rat striatum after L-DOPA treatment. Soc Neurosci Abstr 20: 413Google Scholar
  25. Michel PP, Hefti F (1990) Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 26: 428–435PubMedCrossRefGoogle Scholar
  26. Perry TL, Godin DV, Hansen S (1982) Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33: 305–310PubMedCrossRefGoogle Scholar
  27. Robinson TE, Whishaw IQ (1988) Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res 450: 209–224PubMedCrossRefGoogle Scholar
  28. Rosenberg PA (1988) Catecholamine toxicity in cerebral cortex in dissociated cell culture. J Neurosci 8: 2887–2894PubMedGoogle Scholar
  29. Schmidt CJ, Ritter JK, Somalia PK, Hanson GR, Gibb JW (1985) Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 233: 539–544PubMedGoogle Scholar
  30. Snyder GL, Zigmond MJ (1990) The effects of L-DOPA on in vitro dopamine release from striatum. Brain Res 508: 181–187PubMedCrossRefGoogle Scholar
  31. Snyder GL, Keller RW, Zigmond MJ (1990) Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals. J Pharmacol Exp Ther 253: 867–876PubMedGoogle Scholar
  32. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH (1991) Selective increase of iron in substantia nigra zona compacta of Parkinsonian brains. J Neurochem 56: 978–982PubMedCrossRefGoogle Scholar
  33. Stachowiak MK, Keller RW Jr, Stricker EM, Zigmond MJ (1987) Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage. J Neurosci 7: 1648–1654PubMedGoogle Scholar
  34. Weinberger J, Nieves-Rosa J, Cohen G (1985) Nerve terminal damage in cerebral ischemia: protective effect of alpha-methyl-para-tyrosine. Stroke 16: 864–870Google Scholar
  35. Zhang WQ, Tilson HA, Nanry KP, Hudson PM, Hong JS, Stachowiak MK (1988) Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage. Brain Res 461: 335–342PubMedCrossRefGoogle Scholar
  36. Zigmond MJ, Strieker EM (1989) Animal models of parkinsonism using selective neurotoxins: clinical and basic implications. Int Rev Neurobiol 31: 1–79PubMedCrossRefGoogle Scholar
  37. Zigmond MJ, Hastings TG, Abercrombie ED (1992) Neurochemical responses to 6- hydroxydopamine and L-DOPA therapy: implications for Parkinson’s disease. Ann NY Acad Sci 648: 71–86CrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1997

Authors and Affiliations

  • T. G. Hastings
    • 1
    • 2
  • M. J. Zigmond
    • 1
    • 2
  1. 1.Department of NeurologyUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Department of NeuroscienceUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations